Plain-English translation of NCT07410494 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CAR-NK cell therapy, a treatment that uses immune cells from healthy donors that are genetically modified in the laboratory to recognize and attack cancer cells. Before you receive the cells, doctors will test your tumor to identify which cancer targets are present, then the cells will be customized to match those targets. This personalized approach means the treatment is designed specifically for your cancer.
Many advanced cancers stop responding to standard chemotherapy and radiation, leaving patients with limited options. This trial is exploring whether engineered immune cells can work where traditional treatments have failed, offering a new way to harness the body's natural defenses against cancer.
You likely qualify if…
You likely don't qualify if…
First, your tumor will be analyzed using a biopsy and/or blood test to identify which cancer targets are present and determine which treatment approach is right for you. You will then receive chemotherapy to prepare your body, followed by an infusion of the engineered immune cells. You'll have intensive monitoring for the first month, including blood tests and imaging scans at regular intervals, to track how well the treatment is working and watch for any side effects. Follow-up visits and scans will continue as defined by the study protocol.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China